Biogen's diranersen Phase 2 study showed tau reduction in Alzheimer's but confused experts: The lowest doses had the best results, spurring debate among scientists and rivals.
LONDON — One of the most anticipated Alzheimer’s studies in the past few years has created both enthusiasm and confusion, according to conversations Endpoints News recently …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Biogen's tau-lowering diranersen slows Alzheimer's decline 26% at the lowest dose in Phase 2, but an inverse dose response and a…
Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a…
Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.
The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher…
Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.
A study on Biogen's diranersen found it slowed cognitive decline and has promise in treating Alzheimer's disease, researchers…
